Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track

This article was originally published in The Pink Sheet Daily

Executive Summary

Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.

You may also be interested in...



Euthymics' Sweet Dreams Could Be Realized With $24MM Series A

The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.

Euthymics' Sweet Dreams Could Be Realized With $24MM Series A

The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.

AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing

Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel